tetano
Editor, Senior Moderator
J Med Virol
. 2021 Apr 29.
doi: 10.1002/jmv.27038. Online ahead of print.
Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients
Susannah Leach[SUP] 1 2 [/SUP], Ali M Harandi[SUP] 1 3 [/SUP], Tomas Bergstr?m[SUP] 4 [/SUP], Lars-Magnus Andersson[SUP] 4 5 [/SUP], Staffan Nilsson[SUP] 6 7 [/SUP], Lia van der Hoek[SUP] 8 [/SUP], Magnus Gissl?n[SUP] 4 5 [/SUP]
Affiliations
Abstract
The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV Nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-COV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Disease severity; Endemic coronaviruses; Nucleoprotein-specific antibodies.
. 2021 Apr 29.
doi: 10.1002/jmv.27038. Online ahead of print.
Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients
Susannah Leach[SUP] 1 2 [/SUP], Ali M Harandi[SUP] 1 3 [/SUP], Tomas Bergstr?m[SUP] 4 [/SUP], Lars-Magnus Andersson[SUP] 4 5 [/SUP], Staffan Nilsson[SUP] 6 7 [/SUP], Lia van der Hoek[SUP] 8 [/SUP], Magnus Gissl?n[SUP] 4 5 [/SUP]
Affiliations
- PMID: 33913546
- DOI: 10.1002/jmv.27038
Abstract
The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV Nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-COV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; Disease severity; Endemic coronaviruses; Nucleoprotein-specific antibodies.